Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | GCK | P35557 | 3/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042331 | 0.82 | LMNA (0.55) | GCKLMNAHPGDMEN1KMT2A | |
| SCHEMBL12570192 | 0.82 | MTNR1A (0.44) | GPR139KMT2ATSHR | |
| SCHEMBL3604605 | 0.81 | GCK (0.52) | PPARGGCKALOX5LMNAHPGD | |
| SCHEMBL2662774 | 0.78 | CA12 (0.56) | GCKLMNAHPGDMEN1KMT2A | |
| SCHEMBL1042110 | 0.78 | CA12 (0.56) | GCKLMNAHPGDMEN1KMT2A | |
| SCHEMBL4666903 | 0.78 | GCK (0.55) | GCKLTB4RLTB4R2FFAR1 | |
| SCHEMBL29523345 | 0.78 | LTB4R (0.57) | LTB4RLTB4R2FFAR1ALOX5MEN1 | |
| SCHEMBL29035407 | 0.78 | LTB4R (0.57) | LTB4RLTB4R2FFAR1ALOX5MEN1 | |
| SCHEMBL29523814 | 0.78 | LTB4R (0.57) | LTB4RLTB4R2FFAR1ALOX5MEN1 | |
| SCHEMBL2084645 | 0.76 | GCK (0.59) | PPARAPPARGGCKLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642263-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | PPARA 365/4885PPARG 99/4885GCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.